Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models
Clarisse Thiollier(Inserm), Thomas Mercher(Inserm), Stéphane de Botton(Université Paris-Saclay), Justine Guégan(Institut Gustave Roussy), Paola Rivera-Muñoz(Inserm), Isabelle Radford, Daniel Gautheret(Centre National de la Recherche Scientifique), Arnaud Petit(Sorbonne Université), Paola Ballerini(Sorbonne Université), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Olivier Bernard(Université de Poitiers), Cécile K. Lopez(Inserm), Qiang Wen(Zhejiang Cancer Hospital), Françoise Pflumio(Inserm), Sandrine Poglio(Université Paris-Sud), Philippe Dessen(Centre National de la Recherche Scientifique), Vinciane Mabialah(Université Paris-Sud), Dirk Reinhardt(Society of Paediatric Oncology and Haematology), John D. Crispino(St. Jude Children's Research Hospital), William Vainchenker(Inserm), Olivier Bluteau(Centre National de la Recherche Scientifique), Yann Lécluse(Institut Gustave Roussy), Bastien Gerby(Centre National de la Recherche Scientifique), Nicole Dastugue(Inserm), Judith Landman‐Parker(Sorbonne Université), Yannis Duffourd(Inserm), Cathy Ignacimouttou(Inserm), M’Boyba Diop(Institut Gustave Roussy), Anne-Laure Bauchet(Ipsen (France)), Beat Bornhäuser(University Children's Hospital Zurich)
Cited by 108
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k